Dihydroergotamine mesylate|6190-39-2|(甲磺酸双氢麦角毒碱)-陌孚医药/Medlife

您当前的位置：

Dihydroergotamine mesylate (Synonyms: 甲磺酸双氢麦角毒碱)

目录号: PL05389 纯度: ≥99%

CAS No. :6190-39-2

商品编号	规格	价格	会员价
PL05389-10mg	10mg	¥562.00	请登录
PL05389-50mg	50mg	¥1285.00	请登录
PL05389-100mg	100mg	询价	询价
PL05389-200mg	200mg	询价	询价
PL05389-10mM*1mLinDMSO	10mM*1mLinDMSO	¥803.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Dihydroergotamine mesylate
中文别名	甲磺酸二氢麦角胺;双氢麦角胺甲磺酸盐;甲磺双氢麦角胺;甲磺酸双氢麦角胺;Dihydroergotamine Mesylate 双氢麦角胺甲磺酸盐;二氢麦角胺甲磺酸;甲磺酸二氢麦角胺 USP标准品;甲磺酸二氢有机胺化合物;甲磺蒜二氢唛角鞍
英文名称	Dihydroergotamine mesylate
英文别名	DIHYDROERGOTAMINE MESYLATE;5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman;9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trionemonomethanesulfonate;9,10-dihydroergotaminemesylate;9,10-dihydro-ergotaminmonomethanesulfonate(salt);Agit;Angionorm;D.H.E. 45;Dergotamine;Dihydroergotamine (mesylate);DIHYDROERGOTAMINE MESILATE, EP STANDARD;Dihydroergotamine mesylate,9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotaman-3',6',18-trionemesylate;Dihydroergotamine methanesulfonate salt;DET MS;dhe45;Diergo;dihydroergotamine methanesulfonate;Ergont;Ikaran;Migranal;Morena;Dihydroergotamine mesilate;Dihydergot;Dihytamine;DETMS;9,10-Dihydroergotamine mesylate;Dihydroergotamine monomethanesulfonate;MT 300;81AXN7R2QT;Ergotamine, 9,10-dihydro-, monomethanesulfonate (salt);ST056346;Dihydroergotamine Methanesulfonate
Cas No.	6190-39-2
分子式	C₃₄H₄₁N₅O₈S
分子量	679.78
包装储存	4°C, sealed storage, away from moisture and light In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

产品详情

Dihydroergotamine甲磺酸盐为麦角生物碱，可作用于偏头疼。

生物活性

Dihydroergotamine mesylate is an ergot alkaloid used to treat migraines. Target: 5-HT Receptors Dihydroergotamine is not as effective as sumatriptan or phenothiazines as a single agent for treatment of acute migraine headache; however, when administered with an antiemetic, dihydroergotamine appears to be as effective as opiates, ketorolac, or valproate. Given its nonnarcotic properties, parenteral dihydroergotamine combined with an antiemetic should be considered as effective initial therapy in clinical practice [1]. The introduction of the intranasal formulation of DHE provides both pharmacologic and patient-convenience advantages for use in migraine therapy [2, 3].

性状

Solid

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture and light In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

ClinicalTrial

参考文献

[1]. Colman, I., et al., Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature. Ann Emerg Med, 2005. 45(4): p. 393-401.
[2]. Saper, J.R., et al., DHE in the pharmacotherapy of migraine: potential for a larger role. Headache, 2006. 46 Suppl 4: p. S212-20.
[3]. Schaerlinger, B

溶解度数据	In Vitro: DMSO : 50 mg/mL (73.55 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation